Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Sponsor: Zhuhai Trinomab Pharmaceutical Co., Ltd.
Summary
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Official title: A Large-Sample Real-World Dynamic Cohort Registry: Observing the Clinical Outcomes of Siltartoxatug Injection for Tetanus Prophylaxis Following Injury
Key Details
Gender
All
Age Range
Any - Any
Study Type
OBSERVATIONAL
Enrollment
10000
Start Date
2025-07-31
Completion Date
2029-03-30
Last Updated
2026-01-06
Healthy Volunteers
No
Conditions
Interventions
Siltartoxatug Injection (Brand name: Sintetol®)
The injury and wound conditions of the enrolled patients will be documented. A follow-up at 90 days post-administration will determine the clinical outcome of tetanus prophylaxis, specifically whether tetanus occurred. The registry will also employ selective safety data collection to record adverse reactions and serious adverse events following Siltartoxatug adminstration.
Locations (4)
The Second Affiliated Hospital of Shantou University
Shantou, Guangdong, China
Xiangyun County People's Hospital
Xiangyun, Yunnan, China
Shaoxing Central Hospital
Shaoxing, Zhejiang, China
Zhoushan Putuo District People's Hospital
Zhoushan, Zhejiang, China